40
Cost-effectiveness of RTS,S malaria vaccine candidate in children estimated using a Markov cohort model and Phase 3 trial results

Thursday, March 13, 2014: 12:50 PM
Mount Kenya D 4 (Safari Park Hotel)
Christophe Sauboin , GlaxoSmithKline Vaccines, Wavre, Belgium
Ilse Van Vlaenderen , CHESS In Health, Ternat, Belgium
Laure-Anne Van Bellinghen , CHESS In Health, Ternat, Belgium
Baudouin Standaert , GlaxoSmithKline Vaccines, Wavre, Belgium
See more of: Studies on costing of HIV, Malaria, TB
See more of: Abstracts
<< Previous Abstract | Next Abstract >>